RE:RE:Addressable market
Joemare wrote: I must say it's news. It's all about the penetration rate, 25% of that market within 12-18 months.
Good news today.
They are also conducting another trial(promise) comparing heavily treated patients with and without Trogarzo. If the results are favourable that would be definitely very helpful to convince doctors and patients including Trogarzo in earlier line of treatments which is much bigger(as per company's estimates 30 plus thousand)market to penetrate.
"To compare the virologic, immunologic and clinical outcomes of patients receiving ibalizumabtreatment vs. matched patients not receiving ibalizumab."
https://clinicaltrials.gov/ct2/show/NCT05388474